You may think that with a price-to-sales (or “P/S”) ratio of 21.7x Ascendis Pharma A/S (NASDAQ:ASND) is a stock to avoid completely, seeing as almost half of all the Biotechs companies in the United States have P/S ratios under 11.2x and even P/S lower than 4x aren’t out of the ordinary. Although, it’s not wise to just take the P/S at face value as there may be an explanation why it’s so lofty.
View our latest analysis for Ascendis Pharma
What Does Ascendis Pharma’s Recent Performance Look Like?
Recent times have been advantageous for Ascendis Pharma as its revenues have been rising faster than most other companies. The P/S is probably high because investors think this strong revenue performance will continue. If not, then existing shareholders might be a little nervous about the viability of the share price.
If you’d like to see what analysts are…
